欢迎访问《同济大学学报（医学版）》编辑部！

引用本文：

周振,冯立明,姚旭东,等.神经内分泌前列腺癌生物标志物与治疗靶点研究进展[J].同济大学学报（医学版）,2022,43(2):278-284. [点击复制]
ZHOU Zhen,FENG Liming,YAO Xudong,et al.Research progress of biomarkers and therapeutic targets for neuroendocrine prostate cancer[J].同济大学学报（医学版）,2022,43(2):278-284. [点击复制]

【打印本页】【在线阅读全文】【下载PDF全文】【查看/发表评论】【下载PDF阅读器】【关闭】

本文已被：浏览 232次下载 301次	码上扫一扫！
神经内分泌前列腺癌生物标志物与治疗靶点研究进展
周振,冯立明,姚旭东,叶林
0 字体:加大+\|默认\|缩小-
(南京医科大学上海十院临床医学院泌尿外科，南京211166;新疆沙湾市人民医院普外泌尿科，新疆沙湾832100;同济大学附属第十人民医院泌尿外科，上海200072)

摘要:

神经内分泌前列腺癌(neuroendocrine prostate cancer, NEPC)是晚期前列腺癌治疗耐药的重要原因，目前临床对其早期诊断与治疗的认知仍存在不足。针对这一现状，本文回顾了NEPC近年来新出现的诊断、治疗靶点，拟为今后相关临床工作提供更加全面的诊疗参考。

关键词: 前列腺癌神经内分泌分化生物标志物治疗靶点

DOI：10.12289/j.issn.1008-0392.21326

投稿时间：2021-07-27

基金项目:国家自然科学基金面上项目(81972409、81672549)；上海市自然科学基金(15ZR1433000)

Research progress of biomarkers and therapeutic targets for neuroendocrine prostate cancer

ZHOU Zhen,FENG Liming,YAO Xudong,YE Lin

(Department of Urology, Shanghai Tenth People’s Hospital, Nanjing Medical University, Nanjing 211166, China;Department of General Surgery and Urology, Shawan People’s Hospital, Shawan 832100, Xinjiang Uygur Autonomous Region, China;Department of Urology, Shanghai Tenth People’s Hospital, School of Medicine, Tongji University, Shanghai 200072, China;Department of Urology, Shanghai Tenth People’s Hospital, Nanjing Medical University, Nanjing 211166, China; Department of Urology, Shanghai Tenth People’s Hospital, School of Medicine, Tongji University, Shanghai 200072, China)

Abstract:

The advanced neuroendocrine prostate cancer(NEPC) is frequently resistant to drug therapy, due to lack of its clinical awareness for early diagnosis and treatment. This article reviews the recent research progress on the diagnostic biomarkers and therapeutic targets of NEPC, to provide information for more comprehensive diagnosis and treatment of NEPC in the future.

Key words: prostate cancer neuroendocrine differentiation biomarkers therapeutic target